Comparative Pharmacology
Head-to-head clinical analysis: CHROMALBIN versus CHROMIC CHLORIDE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHROMALBIN versus CHROMIC CHLORIDE IN PLASTIC CONTAINER.
CHROMALBIN vs CHROMIC CHLORIDE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds and stabilizes human serum albumin selectively, labeling it with technetium-99m for diagnostic imaging of blood pool and vascular permeability.
Chromium is an essential trace element that potentiates insulin action, improves glucose tolerance, and enhances protein and lipid metabolism. It is a component of chromodulin, a low-molecular-weight chromium-binding substance that binds to the insulin receptor and activates tyrosine kinase activity, increasing insulin sensitivity.
IV infusion of 1 g over 30 minutes every 6 hours for 7 days.
Intravenous: 10-15 mcg/kg/day of elemental chromium added to parenteral nutrition.
None Documented
None Documented
Terminal elimination half-life: 8.5 hours (range 7-10 h) in adults; prolonged to 12-15 h in hepatic impairment, necessitating dose adjustment.
The terminal elimination half-life of chromium (as Cr(III)) from plasma is approximately 15-41 hours, with a mean of about 24 hours. This long half-life reflects slow clearance from deep tissue compartments.
Renal: 60% as unchanged drug; Biliary/Fecal: 30% as metabolites; 10% other.
Renal excretion of absorbed chromium is the primary route of elimination, accounting for approximately 60-80% of the absorbed dose. Biliary/fecal excretion accounts for <10%.
Category C
Category C
Trace Element Supplement
Trace Element Supplement